Want to see NAMS full AI Analyst Report?
NAMS Stock Chart & Stats
$34.68
-$0.03(-0.12%)
At close: 4:00 PM EST
$34.68
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$21.14 - $42.21
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.06M
Market Cap
$3.47B
Enterprise Value$3.26K
Total Cash (Recent Filing)$636.11M
Total Debt (Recent Filing)$23.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Aug 12, 2026EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.81
Shares Outstanding116,903,980
10 Day Avg. Volume933,636
30 Day Avg. Volume1,055,524
Financial Highlights & Ratios
PEG Ratio0.63
Price to Book (P/B)5.87
Price to Sales (P/S)178.34
P/FCF Ratio-27.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$50.29Price Target Upside45.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$28.61M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low reported debt versus substantial equity provides durable financial flexibility. This conservative capital structure reduces refinancing risk, supports funding of late‑stage trials and regulatory activities, and preserves optionality for partnerships or milestone-driven receipts without immediate liquidity stress.
High Gross MarginsA reported gross margin near 97.5% implies the product economics are highly favorable once commercialized. High manufacturing/COGS leverage supports strong cash conversion on sales, enabling sustainable profitability potential post-approval and attractive royalty economics under licensing deals.
EU Partnership And CHMP Positive OpinionA CHMP positive opinion plus a commercialization/licensing role for Menarini materially de-risks European market entry. The deal structure (royalties and up to €833M milestones) creates clear pathways to non-dilutive revenue, leverages partner commercial capabilities, and strengthens long-term commercial prospects for obicetrapib.
Bears Say
Substantial Cash BurnSustained negative operating and free cash flow of roughly -$142M TTM is a long‑running structural constraint. Continued burn increases reliance on financing or partner milestones, raises dilution risk, and may force reprioritization or delays in costly trials unless material commercial receipts or financings occur.
Deep Ongoing Losses And Negative MarginsExtremely negative net margins and persistent losses reflect a business still years from profitable operations absent product approval and commercialization. This undermines return metrics (negative ROE noted) and means shareholder value is dependent on successful late‑stage outcomes and realized milestone/royalty streams.
Executive Turnover RiskCOO departure during pivotal development and commercialization phases introduces execution risk for ongoing trials (PREVAIL) and operations. While an advisory agreement aims to preserve continuity, leadership transitions can slow decision-making, complicate program delivery, and increase operational uncertainty in the near‑term.
NewAmsterdam Pharma Company News
NAMS FAQ
What was Newamsterdam Pharma Company N.V.’s price range in the past 12 months?
Newamsterdam Pharma Company N.V. lowest stock price was $21.14 and its highest was $42.20 in the past 12 months.
What is Newamsterdam Pharma Company N.V.’s market cap?
Newamsterdam Pharma Company N.V.’s market cap is $3.47B.
When is Newamsterdam Pharma Company N.V.’s upcoming earnings report date?
Newamsterdam Pharma Company N.V.’s upcoming earnings report date is Aug 12, 2026 which is in 17 days.
How were Newamsterdam Pharma Company N.V.’s earnings last quarter?
Newamsterdam Pharma Company N.V. released its earnings results on May 07, 2026. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.459 by $0.059.
Is Newamsterdam Pharma Company N.V. overvalued?
According to Wall Street analysts Newamsterdam Pharma Company N.V.’s price is currently Undervalued.
Does Newamsterdam Pharma Company N.V. pay dividends?
Newamsterdam Pharma Company N.V. does not currently pay dividends.
What is Newamsterdam Pharma Company N.V.’s EPS estimate?
Newamsterdam Pharma Company N.V.’s EPS estimate is -0.47.
How many shares outstanding does Newamsterdam Pharma Company N.V. have?
Newamsterdam Pharma Company N.V. has 116,903,980 shares outstanding.
What happened to Newamsterdam Pharma Company N.V.’s price movement after its last earnings report?
Newamsterdam Pharma Company N.V. reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.459. Following the earnings report the stock price went up 12.456%.
Which hedge fund is a major shareholder of Newamsterdam Pharma Company N.V.?
Currently, no hedge funds are holding shares in NAMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NewAmsterdam Pharma Company Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.29 (45.00% Upside)
$50.29 (45.00% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 386.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 83%
Bearish news 17%
Bearish news 17%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.48%
Trailing 12-Months
Company Description
Newamsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NAMS Stock 12 Month Forecast
Average Price Target
$50.29
▲(45.00% Upside)
Technical Analysis
Ownership Overview
6.18% Insiders
22.46% Mutual Funds
0.72% Other Institutional Investors
68.78% Public Companies and
Individual Investors